| scholarly article | Q13442814 |
| P50 | author | Nise Yamaguchi | Q47408476 |
| P2093 | author name string | Ingrid A Mayer | |
| Auro Del Giglio | |||
| Venancio Alves | |||
| Andre M Murad | |||
| Artur Malzyner | |||
| Carlos Jc de Andrade | |||
| P2860 | cites work | Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 |
| Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis | Q24601392 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis | Q29616121 | ||
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 | ||
| Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. | Q31144835 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer | Q34063503 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| Coxibs and cardiovascular disease | Q34356732 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial | Q34522758 | ||
| Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. | Q34528550 | ||
| Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases | Q34529188 | ||
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 | ||
| Chemotherapy options for gastric cancer. | Q34616790 | ||
| Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. | Q34803588 | ||
| American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy | Q34935716 | ||
| Epidermal growth factor receptor as a therapeutic target in colorectal cancer | Q35079189 | ||
| Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer | Q35187343 | ||
| Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma | Q36190616 | ||
| Evolving chemotherapy for advanced gastric cancer | Q36348340 | ||
| Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. | Q36591918 | ||
| A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation | Q36608816 | ||
| Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer | Q36641883 | ||
| A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer | Q36973778 | ||
| Targeted therapy of cancer: new roles for pathologists in colorectal cancer | Q37147762 | ||
| Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. | Q40337878 | ||
| Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer | Q40612368 | ||
| Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. | Q40657509 | ||
| Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial | Q44135091 | ||
| The relationship between cyclooxygenase-2 expression and colorectal cancer. | Q44193470 | ||
| Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors | Q44471337 | ||
| Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus | Q44587370 | ||
| Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer | Q46706281 | ||
| Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma | Q46856639 | ||
| A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response | Q46972228 | ||
| Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue | Q47677049 | ||
| Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system | Q47791804 | ||
| Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. | Q53413153 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. | Q53967178 | ||
| EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients | Q62991747 | ||
| Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases | Q72807107 | ||
| Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer | Q73223665 | ||
| Epidermal growth factor-receptor expression correlates with tumor cell proliferation and prognosis in gastric cancer | Q74034197 | ||
| Does the EGFR and VEGF expression predict the prognosis in colon cancer? | Q79330888 | ||
| Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas | Q79800177 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number | Q81562524 | ||
| P433 | issue | 1 | |
| P921 | main subject | feasibility study | Q755009 |
| P304 | page(s) | 57-66 | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | Journal of gastrointestinal oncology | Q26842467 |
| P1476 | title | Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study | |
| P478 | volume | 5 |
| Q35194655 | Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis |
| Q48129186 | Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS. |
| Q28544659 | Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics |
Search more.